


Supplementary figure 2. Treatment continuation in NMOSD patients without COVID-19. Strategies for the prevention of complications.



**Oral steroids, azathioprine and mycophenolate mofetil.**

**A-**Treatment interruption in all cases.

**B-**Treatment continuation in all cases.

**C-**Treatment interruption only in patients with grade 1 lymphopenia or worse.

**D-**Treatment interruption only in patients with grade 2 lymphopenia or worse.

- E-Treatment interruption only in patients with grade 3 lymphopenia or worse.
- F-Treatment interruption only in patients with grade 4 lymphopenia.
- G-No access to this treatment.

### **Rituximab**

- A-Postpone next dose in all cases
- B-Continue with usual schedule in all cases.
- C-Continue with usual schedule only in patients with high disease activity, regardless of CD19 CD20 value, because they are considered not useful for decision making.
- D-Continue with usual schedule only in patients with high disease activity, regardless of CD19 CD20 value, because of lack of test availability.
- E-Continue with usual schedule only in patients with high disease activity, depending on CD 19 CD 20 value.
- F-I do not have access to this therapy in my professional practice.

### **Tocilizumab**

- A-Treatment interruption in all cases.
- B-Treatment continuation in all cases.
- C-Treatment interruption only in patients with neutropenia.
- D-I do not have access to this therapy in my professional practice.

### **Eculizumab**

- A-Treatment interruption in all cases.
- B-Treatment continuation in all cases.
- C-Treatment interruption only in patients with grade 1 lymphopenia or worse.
- D-Treatment interruption only in patients with grade 2 lymphopenia or worse
- E-Treatment interruption only in patients with grade 3 lymphopenia or worse.
- F-Treatment interruption only in patients with grade 4 lymphopenia.
- G-I do not have access to this therapy in my professional practice.